Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/EVOTEC-SE-436047/news/EQS-Adhoc-Evotec-SE-Positive-Phase-IIb-Daten-fur-P2X3-Antagonist-in-Patienten-36051242/?utm_source=whatsapp&utm_medium=social&utm_campaign=share